每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ 每经AI快讯，丸美生物（SH 603983，收盘价：36.03元）10月30日晚间发布三季度业绩公告称，2025年 前三季度营收约24.5亿元，同比增加25.51%；归属于上市公司股东的净利润约2.44亿元，同比增加 2.13%；基本每股收益0.61元，同比增加1.67%。 截至发稿，丸美生物市值为144亿元。 （记者 曾健辉） ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-032 关于收到中国证券监督管理委员会广东监管局 行政监管措施决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广东丸美生物技术股份有限公司（以下简称"公司"）及相关人员于近日 收到中国证券监督管理委员会广东监管局（以下简称"广东证监局"）出具的《中 国证券监督管理委员会广东监管局行政监管措施决定书》（﹝2025﹞119 号）（以 下简称"决定书"），现将相关情况公告如下： 一、决定书的主要内容 广东丸美生物技术股份有限公司、孙怀庆、程迪、王开慧： 根据《上市公司现场检查规则》（证监会公告〔2025〕5 号）等规定，我局 对广东丸美生物技术股份有限公司（以下简称丸美生物或公司）进行了现场检查， 发现公司存在以下问题： 一、财务核算不规范 广东丸美生物技术股份有限公司董事会 2025年10月31日 公司及相关人员收到《决定书》后，高度重视《决定书》中指出的问题，公 司及相关人员将严格按照广东证监局的要求及时进行整改，认真总结并吸取教训， 切实提高合 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-031 广东丸美生物技术股份有限公司 关于2025年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将公司 2025 年第三季度主要经营数据 披露如下： 二、2025 年第三季度公司主要产品和原材料的价格变动情况 （一）主要产品价格变动情况 2025 年第三季度，公司主要产品的价格详见下表： | 主要产品 | 2024 | 年 7-9 | 月平均 | 2025 年 | 7-9 | 月平均 | 变动比率（%） | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 售价（元/支） | | | 售价（元/支） | | | | 眼部类 | | 99.33 | | | 151.81 | | 52.83 | | 护肤类 | | 99.45 | | | 103.95 | | 4 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-030 广东丸美生物技术股份有限公司 关于取消监事会并修订《公司章程》及修订、新增公司 部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广东丸美生物技术股份有限公司（以下简称"公司"）第五届董事会第九次会议， 审议通过了《关于取消监事会并修订<公司章程>及修订、新增公司部分治理制度的 议案》，具体内容如下： | 违反法律、行政法规或者本章程，或者决议内容违 | 反法律、行政法规或者本章程，或者决议内容违反 | | --- | --- | | 反本章程的，股东有权自决议作出之日起 60 日内， | 本章程的，股东有权自决议作出之日起 60 日内，请 | | 请求人民法院撤销。 | 求人民法院撤销。但是，股东会、董事会的会议召 | | | 集程序或者表决方式仅有轻微瑕疵，对决议未产生 | | | 实质影响的除外。 | | | 董事会、股东等相关方对股东会决议的效力存 | | | 在争议的，应当及时向人民法院提起诉讼。在人民 | | | 法院作 ...

证券代码：603983 证券简称：丸美生物 广东丸美生物技术股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广东丸美生物技术股份有限公司 2025 年第三季度报告 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 685,733,810.21 | 14.28 ...

丸美生物公告，第三季度营收为6.86亿元，同比增长14.28%；净利润为6948.16万元，同比增长 11.59%。前三季度营收为24.5亿元，同比增长25.51%；净利润为2.44亿元，同比增长2.13%。 ...

Core Viewpoint - The cosmetics sector experienced a decline of 2.02% on October 30, with Shuiyang Co. leading the drop. The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1]. Group 1: Market Performance - The cosmetics sector saw a significant drop, with Shuiyang Co. falling by 10.25% to a closing price of 19.87 [2]. - Other notable declines included Qing Song Co. at -3.38%, Beitaini at -2.79%, and Shanghai Jahwa at -2.67% [2]. - The overall trading volume for the cosmetics sector was substantial, with Shuiyang Co. alone accounting for a trading volume of 399,500 shares and a transaction value of 817 million [2]. Group 2: Capital Flow - The cosmetics sector experienced a net outflow of 111 million from main funds, while retail investors saw a net inflow of 39.41 million [2]. - The main funds showed varying levels of inflow and outflow across different companies, with Qingdao Jinwang receiving a net inflow of 53.98 million, while LaFang Home Care faced a net outflow of 7.27 million [3]. - The overall sentiment in the sector indicates a cautious approach from institutional investors, contrasting with the slight interest from retail investors [2][3].

Market Overview - The cosmetics sector increased by 0.77% on October 29, with Marubi Biological leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Individual Stock Performance - Marubi Biological (603983) closed at 36.66, up 3.74% with a trading volume of 41,500 shares and a turnover of 150 million yuan [1] - Babi Co. (920123) closed at 18.06, up 3.56% with a trading volume of 23,700 shares and a turnover of 41.72 million yuan [1] - Shanghai Jahwa (600315) closed at 25.46, up 2.74% with a trading volume of 154,500 shares and a turnover of 392 million yuan [1] - Betaini (300957) closed at 45.83, up 0.57% with a trading volume of 33,400 shares and a turnover of 152 million yuan [1] - Other notable performances include Proya (603605) at 76.87, up 0.18%, and Water Sheep Co. (300740) at 22.14, up 0.09% [1] Fund Flow Analysis - The cosmetics sector experienced a net outflow of 89.37 million yuan from institutional investors and 51.47 million yuan from retail investors, while individual investors saw a net inflow of 141 million yuan [2] - The detailed fund flow for individual stocks shows that Shanghai Jahwa had a net outflow of 32.36 million yuan from institutional investors [3] - Marubi Biological had a net inflow of 4.95 million yuan from institutional investors, but a net outflow of 8.77 million yuan from retail investors [3]

Core Viewpoint - The article discusses the contrasting performance of Proya, a leading domestic beauty brand in China, highlighting its impressive sales during the Double Eleven shopping festival while facing significant stock price declines and slowing growth in recent financial results [1][3][5]. Group 1: Company Performance - Proya achieved over 1 billion yuan in sales within the first four hours of the Double Eleven pre-sale, becoming the top brand in the beauty category [1]. - Despite the sales success, Proya's stock price has dropped over 20% since May and more than 40% from its peak in 2023 [1]. - In the first half of 2025, Proya reported revenue of 5.362 billion yuan, a year-on-year increase of 7.21%, and a net profit of 799 million yuan, up 13.80% [5][6]. - The revenue growth rate of Proya in the first half of 2025 is the lowest since its listing in 2017, significantly down from 37.9% in the same period last year [6][9]. Group 2: Brand and Market Dynamics - Proya's main brand, which contributes nearly 80% of its revenue, saw a slight decline in revenue of 0.08% in the first half of 2025, marking its first negative growth in five years [10][11]. - The company has been expanding its multi-brand strategy through acquisitions, but the contributions from these new brands remain limited, with combined revenue from new brands being less than 1 billion yuan [14][16]. - The beauty market is becoming increasingly competitive, with mid-tier brands gaining market share while top brands like Proya are losing ground [24][25]. Group 3: Financial and Strategic Challenges - Proya's sales expenses reached 5.161 billion yuan in 2024, accounting for 47.88% of its revenue, while its R&D expenses were only 210 million yuan, indicating a heavy reliance on marketing over innovation [17]. - The company faces challenges in maintaining competitive product offerings, as it has not introduced new blockbuster products since its initial success [19]. - Proya's online sales accounted for over 95% of its revenue in 2024, highlighting its dependence on digital channels [33]. Group 4: Future Outlook - The article suggests that Proya is undervalued from an investment perspective, but it faces significant competition from both domestic and international brands [42]. - The company is undergoing leadership changes, which may introduce uncertainty into its operations [43]. - Proya must accelerate innovation and reform to realize its potential as a leading beauty brand in a rapidly evolving market [45].

Core Viewpoint - The article highlights the contrasting performance of Proya, a leading domestic beauty brand, which achieved over 10 billion yuan in revenue for the first time while its stock price has significantly declined by over 20% since May and over 40% from its peak in 2023 [1][3][4]. Group 1: Company Performance - Proya's sales during the Double Eleven pre-sale event were strong, with the brand ranking first in the beauty category and achieving over 100 million yuan in sales shortly after the event began [1]. - In the first half of 2025, Proya reported revenue of 5.362 billion yuan, a year-on-year increase of 7.21%, and a net profit of 799 million yuan, up 13.80% [4][5]. - However, the revenue growth rate of Proya in the first half of 2025 is the lowest since its listing in 2017, significantly down from 37.9% in the same period last year [5][8]. Group 2: Brand and Market Dynamics - The main brand Proya, which contributes nearly 80% of the company's revenue, saw a slight decline in revenue of 0.08% to 3.979 billion yuan, marking its first negative growth in five years [9][10]. - Proya's multi-brand strategy, including acquisitions of domestic and international brands, has not significantly improved overall performance, with new brands contributing only 18.4% to total revenue [12][13]. Group 3: Competitive Landscape - The beauty market is becoming increasingly competitive, with other brands like Mao Geping and Marubi showing revenue growth rates above 30%, while Proya's growth has slowed [8][22]. - The overall beauty and skincare market saw a sales increase of 10.1% in the first half of 2025, indicating a shift in market dynamics towards mid-tier brands [22][24]. Group 4: Financial Metrics and Investment - Proya's sales expenses reached 5.161 billion yuan in 2024, accounting for 47.88% of its revenue, while R&D expenses were only 210 million yuan, highlighting a significant imbalance [16]. - The company is facing challenges in maintaining its market position due to high reliance on marketing and low R&D investment, which is critical in a market increasingly focused on product efficacy and ingredients [34][36]. Group 5: Future Outlook - Proya's management has proposed a "Double Ten Strategy" aiming to enter the top ten global cosmetics companies within the next decade, but the company faces significant valuation challenges compared to international giants [19][20]. - The article suggests that Proya must accelerate innovation and reform to realize its potential as a leading brand in the beauty industry [46].